+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort



DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort



Clinical and Experimental Rheumatology 35(6): 936-942



To describe treatment patterns in the Swedish early psoriatic arthritis cohort (SwePsA) of the mono-/oligo-arthritic (M/O) and polyarthritis (P) and identify early predictive factors for treatment with disease-modifying anti-rheumatic (DMARD), non-steroidal anti-inflammatory drugs (NSAID), and tumour necrosis factor inhibition (TNFi) after 5 years. Data for 198 M/O and P PsA were obtained within the programme for SwePsA. Multinomial and binary logistic regression analyses were used to assess the association between early predictive factors and treatment after 5 years adjusted for age at inclusion. The analysis of DMARD/NSAID was adjusted for medication at inclusion. After inclusion visit, DMARD was prescribed in 30% of M/O and 56% of P PsA; mainly methotrexate. TNFi was not prescribed at inclusion, but 23 patients were treated at 5-year follow-up. The adjusted OR (95% CI) for treatment with both DMARD and NSAID after 5 years was 3.65 (1.34 - 9.89) (p=0.010) for Disease Activity Score 28 (DAS28) >3.2 and 2.90 (1.20-6.99) (p=0.038) for Disease Activity Index in Psoriatic Arthritis (DAPSA) >14 at inclusion. TNFi treatment was, after adjusting for age, associated with high erythrocyte sedimentation rate (p=0.0043), high C-reactive protein (p=0.013), DAPSA (p<0.001), not reaching minimal disease activity (p=0.001) high health assessment questionnaire (p=0.001), patient's overall assessment on the visual analogue scale (VAS) (p=0.009), high pain VAS (p=0.007), and high number of tender and swollen joints (p=0.031) at inclusion. Disease activity in early M/O and P PsA is to be considered in deciding the level of health care assessment and future pharmacological treatment. DAS28 >3.2 and DAPSA>14 early in the disease predict subsequent treatment with DMARD. For prediction of biological treatment, not reaching MDA at onset of disease, would be the composite index of choice.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059575898

Download citation: RISBibTeXText

PMID: 28628468


Related references

Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Annals of the Rheumatic Diseases 73(2): 407-413, 2014

AB0930DAREA/DAPSA (disease activity score for reactive arthritis/disease activity index for psoriatic arthritis) and related variables in patients with psoriatic arthritis (PSA):. Annals of the Rheumatic Diseases 71(Suppl 3): 691.18-691, 2013

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis and Rheumatism 56(2): 476-488, 2007

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Annals of the Rheumatic Diseases 68(5): 702-709, 2009

SAT0573Clinical and Treatment Patterns in Early Psoriatic Arthritis: Comparison with Early Rheumatoid Arthritis in a Recent Onset Arthritis Cohort: Table 1. Annals of the Rheumatic Diseases 74(Suppl 2): 868.1-868, 2015

Sat0405Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol. Annals of the Rheumatic Diseases 73(Suppl 2): 741.1-741, 2014

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. Annals of the Rheumatic Diseases 77(12): 1736-1741, 2018

SAT0300Nail psoriasis per se does not predict psoriatic arthritis: Analysis of risk factors in a cohort of italian psoriatic patients:. Annals of the Rheumatic Diseases 71(Suppl 3): 573.3-573, 2013

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis. Patient 11(3): 329-340, 2018

Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clinical and Experimental Rheumatology 34(1): 68-75, 2016

Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis?. Modern Rheumatology 21(1): 106-108, 2011

Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. Clinical and Experimental Rheumatology 33(5 Suppl 93): S48-S50, 2015

SAT0398Application of Disease Activity Index for Psoriatic Arthritis (DAPSA) in A Cohort of Patients Followed in The Institute of Rheumatology Prague. Annals of the Rheumatic Diseases 75(Suppl 2): 813.2-813, 2016

Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Annals of the Rheumatic Diseases 72(10): 1675-1679, 2013

Liver biopsy findings in patients with rheumatoid arthritis and psoriatic arthritis on long term treatment with methotrexate. Arthritis & Rheumatism 29(4 Suppl.): S76, 1986